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ABSTRACT 
Reliable experimental determination of the solubility of active pharmaceutical ingredients (APIs) in solvents and the correlation for solubility 
analysis is crucial for the accelerated design and optimization of procedures in the drug industry for isolation, purification and formulation. In 
this study, the antihypercholesterolemic drug rosuvastatin was evaluated for solubility, effect of pH, compatibity with various exepients. In this 
research, the rosuvastatin, an antihypercholesterolemic drug was analysed for solubility, pH effect, and compatibility with different excipients. 
Drug dispersion  subjected to Differential scanning calorimetry and X-ray powder diffractometry. 
Keywords: Hypercholesterolaemia, HMG-CoA reductase inhibitors, DSC, XRPD 
 
Article Info: Received 02 April 2019;    Review Completed 06 June 2019;    Accepted 10 June 2019;    Available online 22 June 2019 
Cite this article as:  
Rajput P,  Gauniya A, Preformulation Studies of Rosuvastatin , Journal of Drug Delivery and Therapeutics. 2019; 9(3-
s):729-735    http://dx.doi.org/10.22270/jddt.v9i3-s.2968 
*Address for Correspondence:  




Cholesterol is a fat-like, smooth, waxy substance that is a 
naturally occurring substance of all body's cells. Our body 
produces all cholesterol that is required.High cholesterol 
increases the possibility of coronary heart disease (CHD) like 
heart attack, and stroke. Significant amounts cholesterol 
present in the blood can induce sticky clusters on the 
arterial walls (aptly named plaque). Plaque may restrict or 
interrupt blood circulation  to the brain, heart, as well as 
other organs inevitably.1 Blood cells become captured to 
produce clots on the plaque. Clots can sometimes 
spontaneously  break loose and interrupt blood supply 
within an artery altogether, triggering a stroke or heart 
attack.2   
Hypercholesterolaemia has a central role in atherosclerosis 
and cardiovascular disease evolution. The likelihood of 
atherosclerosis process transition to coronary heart disease 
is rising rapidly as total serum cholesterol or low-density 
lipoprotein (LDL) cholesterol  goes up at individual and 
population levels.3  
The inhibitors of HMG-CoA reductase are reversible 
inhibitors of the HMG-CoA reductase microsomal enzyme 
which transforms HMG-CoA to mevalonate. HMG-CoA is an 
essential  but rate limiting step in the biosynthesis of 
cholesterol. Inhibition of HMG-CoA reductase by HMG-CoA 
reductase inhibitors cuts intracellular cholesterol 
biosynthesis, causes a transcriptionally upregulated release 
of microsomal HMG-CoA reductase on the cell surface LDL 
receptor.4  
Pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, 
and cerivastatin are the HMG-CoA reductase inhibitors 
principally used in clinical applications. Simvastatin, 
lovastatin and pravastatin is extracted from fungi .5  
Rosuvastatin also belongs to the HMG CoA reductase 
inhibitors ("statins"). The activity of rosuvastatin in 
inhibiting HMG-COA reductase has been studied in the 
purified human catalytic domain showed that rosuvastatin 
was more potent than other available statins with the least 
50% inhibitory concentration [IC50] of 5.4Nm.6,7 
Previous research have demonstrated that rosuvastatin has 
highest amount of binding interactions with active site of the 
enzyme .Rosuvastatin and atorvastatin have additional 
interaction with the enzyme not seen with the other 
synthetic statins. These differences in the number and types 
of bonds between the statin and enzyme may explain the 
relatively greater efficacy of atorvastatin and rosuvastatin to 
lower LDL- cholesterol. Through in-vitro and in-vivo studies, 
the premise that greater binding to the enzyme results into 
higher statin potency appears to be proved.8 
Rosuvastatin ((3R,5S,6E)-7- [4-(4-fluorophenyl)-6- (1-
methylrthyl)-2- [methyl (methylsulfonyl) amino]-5-
pyrimidinyl]-3, 5-dihydroxy-6-heptenoic acid) was approved 
in 2003 by the FDA and is sold by AstraZeneca as Crestor®.  
It is sparingly soluble in water and methanol and slightly 
soluble in ethanol. It has a melting point of 122 °C, and 1 % 
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suspension of the drug gives a pH of 6. It has been reported 
that it is a blend of crystalline and amorphous forms, which 
ultimately determines its solubility and bioavailability in in-
vivo studies. It shows maximum stability at pH 5 in buffered 
pH solution and pH 6 & 7 in un-buffered pH solutions. 
Because of its greater solubility, stability at higher pH (pH 6-
9) values and amphoteric nature, it is well absorbed 
throughout the gastrointestinal tract and more 
predominantly from small intestine.9 
 
Figure 1.: Structure of Rosuvastatin. 
Solubility and permeability (including metabolic 
transformation) of drugs are essential parameters 
determining bioavailability. Rosuvastatin calcium is a BCS 
class II drug. Permeability of BCS class II drugs over the 
intestinal membrane is fast, and hence the absorption will 
mainly be determined by the dissolution rate of the drug in 
the GI fluids. 10Therefore, ways to enhance the dissolution 
rate of poorly water-soluble drugs becomes a challenge. 11 
Different methods are employed to improve the dissolution 
characteristics of poorly water-soluble drugs like 
solubilization, pH adjustment, cosolvents, microemulsion, 
self emulsification, polymeric modification, drug 
complexation, and particle size reduction, use of a surfactant 
as a solubilising agent, the pro-drug approach and dry 
dispersions. 12 This study aimed to prepare ternary solid 
dispersions granules for a poorly Water-soluble drug 
Rosuvastatin to improve its solubility. 
MATERIALS AND METHODS  
Chemical reagents 
All the chemicals used in this study were obtained from Hi-
Media Laboratories Pvt. Ltd. (Mumbai, India), Sigma-Aldrich 
Chemical Co. (Milwaukee, WI, USA), and SD Fine-Chem. Ltd. 
(Mumbai, India). All the chemicals used in this study were of 
analytical grade. 
Preformulation Study 
Preformulation testing is an investigation of physical and 
chemical properties of a drug substance alone and when 
combined with excipients. It is the first step in the rational 
development of dosage forms.13 
Solubility studies  
The solubility of Rosuvastatin was studied in various 
aqueous and non-aqueous solvents. 10 mg of drug was taken 
in 10 ml of each solvent at room temperature in screw-
capped test tubes and shaken for 30 minutes in a sonicator. 
The solubility of Rosuvastatin at Range of pH: 
Equilibrium solubility measured at a range of pH values 
shows pH dependence. The compound Rosuvastatin is 
relatively soluble at pH values above 4 and highly soluble at 
pH 6.6 citrate buffers.  
Powder Flow Properties: - 
When limited amounts of drugs are available, powder flow 
properties can be evaluated by measurements of bulk 
density and angle of repose. Changes in particles size and 
shape are significant as an increase in crystal size, or a more 
uniform shape will lead to a small angle of repose and a 
smaller Carr’s index. 
Compatibility Studies 
One of the requirements for the selection of suitable 
excipients or carrier for the pharmaceutical formulation is 
its compatibility. Rosuvastatin was mixed with the various 
excipients in the different ratio(s). Further, it was stored in 
sealed glass vials and subjected to varying conditions of 
temperature and humidity (25°C/60%RH, 30°C/65%RH, 
40°C/75%RH.) 
After the completion of the specified period, blends were 
evaluated for their physical change, moisture content, and 
impurity profile. 
Preparation of Solid Dispersions 
The basic model used in the present study consists of 
multicomponent blends of drug substances with excipients, 
and stored in closed vials for specific periods of time. 
Samples were analyzed for stability (appearance, color, etc.) 
after specified period of  storage. This formulation was made 
using the Solvent Evaporation method The three different 
ratios of Rosuvastatin (drug) to KollidoneVA64 (carrier) 
were 1:9; 3:7; and 7:3. Rosuvastatin and KollidoneVA64 
were added to a beaker containing the required amount of 
ethanol (solvent). Once these two components were 
dissolved in the solvent, NeusilinUS2 (adsorbent) was added 
and thoroughly mixed. The slurry formed with the solution 
of Rosuvastatin and KollidonVA64 in ethanol, and 
NeusilinUS2 was dried. The product was then stored in an 
airtight container in a dark, cool place until further analysis.  
Differential Scanning Calorimetry (DSC) 
The DSC curves of each mixture were obtained using a 
Mettler Toledo DSC 25 measuring cell equipped with a heat 
flow sensor and joined via interface TA Controller TC 15 to a 
computer. The measurements were driven by STARe 
software. Samples for DSC measurements were sealed in 40-
μl standard aluminium crucibles with a single hole punched 
in the lid. An empty pan of the same type was employed as a 
reference. The DSC instrument was calibrated with the 
melting point of indium (156.6 °C) as a standard. DSC scans 
of each mixture were performed at a heating rate of 5 °C 
min−1 in the temperature range of 30–170 °C. The DSC cell 
was purged with a stream of dry argon at a rate of 50 cm3 
min−1. Experiments were performed in triplicate, and the 
mean values were calculated.14 
X-Ray Powder Diffractometry 
Powder diffraction patterns of all samples were completed 
over the range 2θ from 5° to 40°, at steps of 0.0084° and a 
counting time of 1.00 ° min−1 using PAN analytical X-Pert 
Pro V1.6 with X-Pert Data Collector V2.1 software was used 
equipped with a CuKα2 anode tube and diffract meter of 
radius 240 mm. 
RESULTS AND DISCUSSION 
Result of Preformulation Study: 
Rosuvastatin is an off white to white crystalline powder, 
with a  melting point of 122○C.Solubility profile of 
rosuvastatin is tabulated in Table 1 and 2. Rosuvastatin is 
relatively soluble at pH values above 4 and highly soluble at 
pH 6.6 citrate buffers. The physical characterization of the 
dry dispersion is tabulated in Table 4 
.  
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Table 1 Solubility profile of Rosuvastatin with various solvents 
Solvent* Value Inference 
Water 8.86e-02 g/l Very Slightly Soluble 
Dimethyl Formamide 10.0 mg/ml  Sparingly Soluble 
Ethanol 0.86 mg/1000ml  Very  Slightly Soluble 
Methanol 0.95mg/ml  Slightly Soluble 
0.1M HCl 28 mg/ml  Soluble 
0.1 M NaOH 1 mg/ml   Slightly Soluble 
DMSO 14 mg/ml Sparingly Soluble 
* Solubility (at 25 °C) 
Table 2 Solubility profile of rosuvastatin at range of pH 
Buffer  Solubility* Final pH 
pH 1.2 HCL Acid (0.1N) 0.5±0.0 1.2 
pH 1.2 HCL Buffer ■ 0.5±0.0 1.2 
pH3.6 Acid phthalate Buffer■   1.6±0.1 4.1 
pH 4.0 Acid phthalate Buffer ■ 2.2±0.2 4.5 
pH 4.6 Neutralized phthalate Buffer■   3.7±0.2 5.0 
pH5.6 Neutralized phthalate Buffer■   9.2± 0.5 5.3 
pH6.0 Phosphate Buffer■    10.7± 0.3 5.6 
pH 6.6 Citrate Buffer■  (0.005M) 48.8± 0.6 6.7 
pH7.0 Phosphate Buffer ■ 17.1± 0.0 6.8 
ph7.4 Phosphate Buffer ■ 21.0± 0.7 7.1 
Deionised water  7.8± 0.1 7.0 
* Solubility (at 25 °C)  ■ USP 
 
Compatibility Study 
Some factors that may have pertinent effect on the stability 
of drug  in the presence of additives are the chemical nature 
of the excipient, drug to excipient proportion, humidity, 
microenvironmental pH of the medication-excipient blend, 
temperature, and light. The model allowed identification of 
the potential roles of all of these factors on dosage form 
stability 14 Drug and excipient compatibility data for 
appearance and moisture content were observed and 
recorded in Table3 
 
Table 2: Rosuvastatin compatibility with excipients 
Sample  Observation 
 Initial 30 days 60 days 
α β γ α β γ α β γ 
Drug  Off white crystalline powder * * * * * * 
Drug +Kollidone VA64 Off white crystalline powder * * * * * * 
Drug+Neusilin Us2 Off white crystalline powder * * * * * * 
Drug+Indium Off white crystalline powder * * * * * * 
Drug+Zinc Off white crystalline powder * * * * * * 
α =25 ± 2° C/ 60 ± 5% RH         β=30 ± 2° C/ 65 ± 5% RH   γ= 40 ± 2° C/ 65 ± 5% RH                   *= No Change 
 
Physical Characterization:  
The granules of all the formulations were evaluated for angle 
of repose, LBD, TBD, compressibility index and Hausner‟s 
ratio. From the above studies, the results of the 
compressibility index (<15), also Hausner’s ratio (<1.25) 
indicate excellent flow properties of the granules.
 
Table 4: Physical characterization of the dry dispersion 




Hausner ratio %Compressibility index  
T1 29.43 0.60 0.75 1.25 25 
T2 27.46 0.64 0.78 1.21 21.8 
T3 28.31 0.66 0.78 1.18 18.18 
T4 27.49 0.71 0.81 1.14 14.08 
T5 25.45 0.63 0.71 1.12 12.69 
T6 23.45 0.61 0.68 1.11 11.47 
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Prepared Solid Dispersion  
The solid dispersions and the mixtures were subjected to 
tests to study the changes that might take place with the 
drug when formulated into a solid dispersion. The study also 
included the characterisation of the ternary solid dispersion 
granules concerning their physicochemical properties. The 
solvent method is the preparation of a solution containing 
both matrix material and drug. The second step involves the 
removal of solvent(s), resulting in the formation of solid 
dispersion. Rosuvastatin and KollidonVA64 Solid Dispersion. 
Four ternary solid dispersions were prepared using 10% 
w/w, 30% w/w, 50% w/w and 70% w/w of Rosuvastatin 
and 90% w/w, 70% w/w, 50% w/w and 30% w/w of 
KollidonVA64   respectively, coated on 20%w/w of Neusilin 
US2 (adsorbent). KollidonVA64 was used as a carrier for the 
solid dispersions. NeusilinUS2, which is a porous material 
having a large surface area, was used as an adsorbent. When 
preparing the solid dispersions by the solvent evaporation 
method, the slurry was made with NeusilinUS2 and the 
solution of the drug at different concentrations and 
KollidonVA64. The ternary solid dispersions were also 
subjected to stability studies for two months under different 
temperatures (300C, 350C, 400C, and 450C) and relative 
humidity conditions (100%, 75.29 ±.12%, 54.38± .23 and 
23.11±0.25% RH). 
Differential Scanning Calorimetery 
Differential Scanning Calorimetric (DSC) studies were 
performed on the ingredients used to make the ternary solid 
dispersions, which are Rosuvastatin, KollidonVA64 (K), and 
NeusilinUS2 (N). DSC experiments have been conducted to 
detect any interaction between the various components and 
to test crystallinity variations. . Thermograms for solid 
dispersions formulations containing ten %w/w, 30% w/w 
and 50% w/w Rosuvastatin show flat lines, indicating that 
the drug might be completely amorphous (Figure 1). The one 
for the solid dispersions containing 70% w/w Rosuvastatin 
and 30% w/w KollidonVA64 shows the peak of minimal 
intensity for Rosuvastatin, suggesting that some 
Rosuvastatin might be crystalline. 
 
 
Figure 1: DSC thermo gram showing from top to bottom: NeusilinUS2, KollidonVA64, Rosuvastatin, 10% R+K SD, 30% R+K SD, 
50% R+K SD, 70%  R+K SD 
X-Ray Powder Diffractometry 
X-Ray Powder Diffractometry (XRPD), gives an accurate 
picture of any crystallinity occur-ring with a substance when 
the crystallography is recorded. The crystallography of the 
drug indomethacin (I) was compared with that of the various 
physical mixtures and solid dispersions. XRPD studies 
provide insight into how crystalline or amorphous the drug 
has become. Solid dispersions were subjected to stress under 
accelerated stability conditions and subsequently tested for 
recrystallisation. For this purpose, the four solid dispersions, 
prepared previously, were kept at temperatures of 30°C, 
35°C and 40°C and relative humidity conditions of 100%, 
75.29 ±.12%, and 54.38±.23 for two months.  
Samples were taken at the end of the two months and tested 
for recrystallisation. The crystallography for the four solid 
dispersions prepared. is shown in  Figures 2 to 5 shows the 
crystallography for the solid dispersions kept at 30°C, 35°C, 
and 40°C for two months. Figures 6 to 8  shows the 
crystallography for the solid dispersions kept in 100%, 75.29 




Figure 2 XPRD for Rosuvastatin and four solid dispersions: a- Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 
70% R+K SD 
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Figure 3 XPRD of Solid dispersions kept at 300C for Rosuvastatin and four solid dispersions for a period of two months: a- 
Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
 
Figure 4 XPRD of Solid dispersions kept at 350C for Rosuvastatin and four solid dispersions for a period of two months: a- 
Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
 
Figure 5 XPRD of Solid dispersions kept at 40°C for Rosuvastatin and four solid dispersions for a period of two months: a- 
Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
 
Figure 6  XPRD of Solid dispersions kept at 100% RH for a period of two months for Rosuvastatin and four solid dispersions for 
a period of two months: a- Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
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Figure 7  XPRD of Solid dispersions kept at 75.29±0.12% RH for a period of two months for Rosuvastatin and four solid 
dispersions for a period of two months: a- Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
 
Figure 8 XPRD of Solid dispersions kept at 54.38± .23 RH for a period of two months for Rosuvastatin and four solid dispersions 
for a period of two months: a- Rosuvastatin; b-10%R+K SD; c-30% R+K SD; d-50% R+K SD; e- 70% R+K SD. 
 
XPRD results for solid dispersions, seen in Figure show no 
peaks for indome-thacin suggesting a good reduction in the 
crystallinity of Rosuvastatin in the solid dispersions. Figures 
show PXRD results for the accelerated stability studies and 
suggest that the solid dis-persion is relatively stable. No 
recrystallization is seen in any solid dispersion samples. A 
very small increase in crystallinity in some of the 70% w/w 
Rosuvastatin and 30% w/w Kollidon VA64 solid dispersion 
is seen. 
CONCLUSION 
All the formulations were relatively stable. None of them 
showed an increase in the intensity of the peaks. These 
findings are extremely important from a commercial point of 
view, as the prepared Solid Dispersion formulation, removes 
a major drawback for Rosuvastatin in therapy.  
Formulating solid dispersions into a dosage form and 
studying its characteristics could be the next step for this 
project.Various proportions of adsorbent and drug can give 
different results. A long term stability study for the 
formulations should be conducted 
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